

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/423,018	10/12/2000		Philip Gotwals	A018	6239
7	590	07/15/2003			
Biogen Inc	_		EXAMINER		
14 Cambridge Center Cambridge, MA 02142				ANDRES, JANET L	
				ART UNIT	PAPER NUMBER
				1646 DATE MAILED: 07/15/2003	21

Please find below and/or attached an Office communication concerning this application or proceeding.

<u>.</u>						
	Applicati n No.	Applicant(s)				
Advisory Action	09/423,018	GOTWALS ET AL.				
Auvisory Action	Examiner	Art Unit				
e.	Janet L. Andres	1646				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
THE REPLY FILED 13 June 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR REPLY [check either a) or b)]						
a) The period for reply expires						
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
2.⊠ The proposed amendment(s) will not be entered because:						
(a) Ithey raise new issues that would require further consideration and/or search (see NOTE below);						
(b) they raise the issue of new matter (see Note below);						
(c) ☑ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) they present additional claims without cancel	ing a corresponding number of f	inally rejected claims.				
NOTE: <u>See Continuation Sheet</u> .						
3. Applicant's reply has overcome the following reject						
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because:						
6. The affidavit or exhibit will NOT be considered bed raised by the Examiner in the final rejection.	ause it is not directed SOLELY	to issues which were newly				
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims w	t(s) a)⊠ will not be entered or b ould be rejected is provided belo)∏ will be entered and an ow or appended.				
The status of the claim(s) is (or will be) as follows:	•					
Claim(s) allowed: 5.						
Claim(s) objected to:						
Claim(s) rejected: <u>1-4,6,7 and 10</u> .						
Claim(s) withdrawn from consideration: 8,9 and 11-21.						
8. ☐ The proposed drawing correction filed on is a) ☐ approved or b) ☐ disapproved by the Examiner.						
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)						
10. Other:						

Continuation She t (PTO-303)

*Continuation of 2. NOTE: Applicant's amendment raises new issues because the claims now specify native molecules and naturally occuring variants. These are molecules that exist in nature and have particular sequences. The issue of whether Applicant has described such sequences sufficiently to convey to the skilled artisan that Applicant was in possesion of such sequences, as required by 35 U.S.C. 112, first paragraph, has not previously been considered. Additionally, the limitation of the claims to molecules homologous to the disclosed sequences requires a new search and new considerations. Limited homology does not in itself provide an expectation that molecules within the scope of the claims would have the same function and the limitation further requires an additional search of the art to identify any molecules that would fall within the specified range. The amendment does not materially reduce or simplify the issues for appeal; while the scope of the claims is narrowed, the issue of enablement commensurate with this scope remains. The question of whether the claims are patentable over the Lin and Jacobs is not affected by the proposed amendment..

YVONNE EYLER, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600